Xiangxue Pharmaceutical

Xiangxue Pharmaceutical is identified in the supplied material as a traditional Chinese medicine-related commercial entity. The available evidence does not establish its founding history, headquarters, ownership, product range, business scale, operating markets, or current corporate status. Its website is listed as https://xiangxue.com, but no website content was supplied to substantiate further details.

The supplied evidence identifies Xiangxue Pharmaceutical with the abbreviated descriptor “TCM · B,” but provides no dated events or historical account. Its founding, development, ownership changes, product launches, listing history, leadership, and current corporate status therefore cannot be established from the available material. The company website is given as https://xiangxue.com; without supporting site content, no further historical details are included.

Associated with traditional Chinese medicine; further positioning is not established by the available evidence.

• Traditional Chinese medicine preparations

  TCM-based medicinal preparations, the core category associated with the brand.

• Herbal medicines

  Herbal and traditional medicine products.

• Traditional supplements

  Traditional health and tonic supplements.

• 2025

  Xiangxue Pharmaceutical fined over false annual report records and fund occupation disclosure

  The company announced the penalty decision: Xiangxue failed to recognize losses from demolished villas as required, resulting in false records in its 2019 annual report, and failed to disclose non-operating occupation of funds by related parties as required. The company was ordered to rectify, warned and fined 6 million yuan; the actual controller and other responsible persons were separately punished. Status: the company announced it had received the administrative penalty decision. Entity involved: Guangzhou Xiangxue Pharmaceutical Co., Ltd.

  Source

• 2025

  Xiangxue Pharmaceutical fined and publicly censured over false annual report records and concealed fund occupation

  Xiangxue Pharmaceutical made false records in its annual report and concealed related-party fund occupation; in 2025 it was fined 6 million yuan by the Guangdong bureau of the China Securities Regulatory Commission, and actual controller Wang Yonghui was fined 10 million yuan. In 2026, it was publicly censured by the Shenzhen Stock Exchange for sharply revising its earnings forecast from a loss of about 600-900 million yuan to 1.2-1.5 billion yuan and failing to timely disclose delisting risk. Fine, public censure, *ST.

  Source

Read more

• 2022.03.04

  Xiangxue donates COVID-19 response supplies to Hong Kong[5]香雪制药捐赠抗疫物资驰援香港wenweipo.com

  Xiangxue Pharmaceutical donated 10,000 sets of herbal products and masks for Hong Kong's COVID-19 response. The supplies arrived on March 4 and were distributed to media organizations and community members in need.

Read more

1. 1Xiangxue Pharmaceutical official websitexiangxue.com
2. 2Xiangxue Pharmaceutical fined over false annual report records and fund occupation disclosuredata.eastmoney.com
3. 3Xiangxue Pharmaceutical fined and publicly censured over false annual report records and concealed fund occupationfinance.sina.com.cn
4. 4Xiangxue Pharmaceutical fined and publicly censured over false annual report records and concealed fund occupationstatic.cninfo.com.cn
5. 5香雪制药捐赠抗疫物资驰援香港wenweipo.com